HIGHLIGHTS
- who: Johannes Levin from the MODAG GmbH, Wendelsheim, Germany Department of Neurology, Ludwig-Maximilians-University Munich, Germany have published the Article: Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial, in the Journal: (JOURNAL) of 20/07/2017
- what: This work provides insight into the binding mechanism of anle138b to small oligomers and its ability to directly modulate these structures during the process of peptide aggregate formation. The aim was to assess the safety . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.